474 related articles for article (PubMed ID: 33203821)
1. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
Ku KB; Shin HJ; Kim HS; Kim BT; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Dec; 30(12):1843-1853. PubMed ID: 33203821
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
[TBL] [Abstract][Full Text] [Related]
4. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Farhat N; Khan AU
J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
Ko M; Jeon S; Ryu WS; Kim S
J Med Virol; 2021 Mar; 93(3):1403-1408. PubMed ID: 32767684
[TBL] [Abstract][Full Text] [Related]
7. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Watashi K
Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
[TBL] [Abstract][Full Text] [Related]
8. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ
Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
10. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
12. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
Touret F; Gilles M; Barral K; Nougairède A; van Helden J; Decroly E; de Lamballerie X; Coutard B
Sci Rep; 2020 Aug; 10(1):13093. PubMed ID: 32753646
[TBL] [Abstract][Full Text] [Related]
13. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
14. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
15. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR
Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
Liang H; Zhao L; Gong X; Hu M; Wang H
Clin Transl Sci; 2021 May; 14(3):1123-1132. PubMed ID: 33606912
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
18. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Akilesh SM; J R; Palanisamy D; Wadhwani A
Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
[TBL] [Abstract][Full Text] [Related]
19. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
20. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
